India Won’t Add Merck’s COVID-19 Pill to National Treatment Protocol, Citing Safety Concerns

India Won’t Add Merck’s COVID-19 Pill to National Treatment Protocol, Citing Safety Concerns
An experimental COVID-19 treatment pill called molnupiravir being developed by Merck & Co. Inc. and Ridgeback Biotherapeutics LP, is seen in this undated photo obtained by Reuters on May 17, 2021. Merck & Co. Inc./Handout via Reuters
Katabella Roberts
Updated:

India’s top health research body announced on Wednesday that it won’t be adding Merck’s COVID-19 antiviral pill molnupiravir to its national treatment protocol, citing concerns over its safety.

The state-run Indian Council of Medical Research (ICMR) said it had become aware of “major safety concerns” that prompted the decision, despite India’s drug regulator in December approving the drug for emergency use.
Katabella Roberts
Katabella Roberts
Author
Katabella Roberts is a news writer for The Epoch Times, focusing primarily on the United States, world, and business news.
Related Topics